DB-SEP15: Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination

Sponsor
Fondation Ophtalmologique Adolphe de Rothschild (Other)
Overall Status
Completed
CT.gov ID
NCT03268096
Collaborator
(none)
182
1
54
3.4

Study Details

Study Description

Brief Summary

Knowledge of the evolution of multiple sclerosis (MS) and its long-term prognostic factors is essential to guide the therapeutic management. However, it remains partial and concerns above all data collected during the first years of the disease. The evolution towards disability can only be assessed after a follow-up of more than 10 years and does not depend solely on the initial inflammatory activity of the disease. We propose to realize a standardized clinical assessment, an optical coherence tomography (OCT) and a cerebral MRI 15 years after the first clinical manifestation of the disease.

Clinical and paraclinical assessment will consist in the realization of additional MRI sequences in order to obtain more precise information on cerebral lesions (unconventional parameters). Optical coherence tomography (new generation device) will also be performed on both eyes to describe the thickness of the different layers of the retina. A clinical evaluation will be performed with the Expanded Disability Status Scale (EDSS).

This study aims:
  1. to describe the current clinical situation of patients (e.g. percentage of patients with moderate or severe disability)

  2. to explore the associations between MRI parameters, those measured with OCT and clinical characteristics (disability)

  3. to explore clinical and paraclinical prognostic factors of pejorative evolution (disability, severe cerebral atrophy, etc.)

Condition or Disease Intervention/Treatment Phase
  • Device: Cerebral MRI and Optical Coherence Tomography

Study Design

Study Type:
Observational
Actual Enrollment :
182 participants
Observational Model:
Case-Only
Time Perspective:
Cross-Sectional
Official Title:
Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination
Actual Study Start Date :
May 3, 2017
Actual Primary Completion Date :
Nov 3, 2021
Actual Study Completion Date :
Nov 3, 2021

Outcome Measures

Primary Outcome Measures

  1. Disability assessed with EDSS (Expanded Disability Status Scale) [Baseline]

    Disability assessment will be carried out using the EDS (Expanded Disability Status) Scale. This scale ranges from 0 to 10. Binary or ordered variables will be considered with various thresholds (for example, a score equal to 3 corresponds to moderate disorders ; a score equal to 6 corresponds to major disorders (need of a stick to walk 100 meters)).

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • First episode of demyelination occurred at least 10 years ago

  • Hospitalized in the neurology department during this episode

  • Insured with a social security scheme

  • Having given his consent to participate in the study

Exclusion Criteria:
  • Contraindications to 3 Tesla MRI and injection of contrast media

  • Benefiting from a legal protection measure

  • Pregnant or nursing mother

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondation Ophtalmologique A. de Rothschild Paris France

Sponsors and Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

Investigators

  • Principal Investigator: Antoine Guéguen, MD, Fondation Ophtalmologique A. de Rothschild

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier:
NCT03268096
Other Study ID Numbers:
  • AGN_2017_6
First Posted:
Aug 31, 2017
Last Update Posted:
Apr 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 22, 2022